TNK2 and breast cancer: ACK1 inhibitor drugs will have a broad prospect of clinical application, and at the same time, ACK1 Y284 phosphorylation as a marker in some breast cancer and pTyr-1114 KDM3A antibodies also has a significant clinical diagnostic value which can be used in patients for ACK1-positive breast cancer screening.